INTRODUCTION:

Oral drug administration/distribution has historically been the most popular option for drug delivery systems. Many oral medication delivery systems have been developed in recent years. Such oral drug delivery systems, such as controlled release and gastroretentive systems, which serve as drug reservoirs and release drugs in a regulated manner over a predetermined amount of time, are likewise the foundation of this review. The goal of the effective controlled release drug delivery system GRDDS, which has been the subject of numerous investigations and research projects, is to raise GRT-Gastroresidency period.

Floating drug delivery systems, swelling systems, high density systems, magnetic systems, mucoadhesive systems, bioadhesive systems, and drug expendable systems are all helpful systems for GRDDS; their goal is to improve drug bioavailability for extended duration within the system. However, due to inadequate absorption or gastrointestinal tract breakdown, some outlier drugs exhibit limited bioavailability. Therefore, gastro-retentive drug delivery systems are designed to address this limitation¹.

GRDDS should have the following ideal characteristics:

1. It should function locally in the stomach;

2. It should not disturb the intestinal environment.

3. The GIT's absorption window should be small.

4. In a high pH region, the drug should be poorly soluble in the GIT.

One of the best drug delivery sites for regulating medication release in the stomach or intestine is the gastro retentive drug delivery system (GRDDS). The medicine in GRDDS is released to the intended site of action, such as the stomach, intestines, duodenum, etc., in a controlled and sustained manner.²

Basic Anatomy and Physiology of Gastrointestinal Track:

GIT is essentially separated into three primary regions, which are:

1. Stomach

· Stomach Proximal: Body, Fundus

· Antrum (pylorus) in the distal stomach

2. The Small Intestine

3. Large Intestine

Figure 1: Basic Anatomy of Gastro-Intestinal Tract

Muscle tubes make up the GIT's interior structure. The muscular tube that connects the mouth to the anus is roughly 9 meters in length. GIT's primary functions include storing food, grinding it, using its nutrients, releasing it gradually into the duodenum, and getting rid of waste products from the body. To improve the development of gastroretentive drug delivery systems, a thorough understanding of the anatomy and physiology of the stomach is necessary³.

About 50 ml of liquid, commonly referred to as stomach gastric fluid or HCL, which has a pH of 1-3, is found in the stomach. The stomach's parietal cells, also known as epithelial cells, produce HCl. The regulation of gastric acid or stomach fluid is the responsibility of the parietal cell. On the other hand, zymogenic cells secrete pepsinase, which is essential for nutritional absorption.

The stomach's J-shaped anatomical structure is made up of three distinct muscle layers: the body, fundus, and pyrophorus (antrum). The stomach's first layer, known as the oblique muscle, is found in the proximal portion; the second layer is situated next to the fundus, which branches off of it; and the third layer is found in the upper section of the stomach. The fundus and body of the proximal tube contain undigested material, while the pylorus serves as an elimination organ and the site of motion mixing, acting as a pump to propel stomach emptying⁴.

The controlled process of gastric emptying comprises several stages. Although gastric emptying occurs in both fed and fasted phases, the stomach's mobility pattern, or migratory myoelectric complex (MMC), differs in each state. An interdigestive series of electrical events occurs during the fasting state. This series, known as the Migrating Myoelectric Complex, is carried out in four stages over the course of 90 to 120 minutes. The cycle ends in the ileum after beginning in the lower oesophagus.

Sir Washington and Wilson discuss the four phases into which the migrating myoelectric complex is further divided.

Phase 1	Basal phase	It shows rare contraction 30-60 min
Phase 2	Pre bust phase	It shows constriction 20-40 min
Phase 3	Burst phase	It shows reliable constriction for minimum period of 10-20 min
Phase 4	Occurs during phase 3-1	0-5 min

Figure 2: Phases Migrating Myoelectric Complexes.

Figure 3: Phases of Migrating Myoelectric Complex.

Requirements For Gastroretention Drug:

The gastric retentive dose form should meet specific requirements based on the anatomy and physiology of the stomach, such as distributing the medicine evenly in the GIT and remaining in the stomach for a long time in gastrointestinal tract, high bioavailability, regulated medication release, etc. The main obstacle in gastric retention is that the dose form needs to be stable and resilient to the pressures generated by the stomach's peristaltic wave (GIT)⁵.

Enhancing the medicine's bioavailability is the primary goal of the gastroretentive drug delivery method. Depending on the site of action, a medication with limited absorption in the GIT has poor absorption and remains in the stomach, GIT, or intestinal tract for an extended period of time. For extended medication retention in the stomach.

The following requirements must be met: the medicine must dissolve slowly, absorb slowly in the stomach, and have a local effect there.

1. It ought to be the intended drug delivery method.

2. The medication release should be depending on pH.

3. Food can stimulate medication absorption.

4. The medicine should dissolve and disintegrate in the gastric juice, and it should be similarly absorbed throughout the GIT.

5. Slow dissolution of drug.

6. Slow absorption of drug.

7. Should be Target drug delivery⁶.

Need of Gastro-Retension:

In the pharmaceutical industry, oral medication delivery is more popular because of its many advantages, including ease of administration, affordability, ease of production, and form flexibility, bioavailability, design, etc. Due to their rapid stomach transition, oral dose forms have low bioavailability problems. This issue primarily arises when the intestinal pH is alkaline and the solubility is poor. The drug's limited solubility caused it to work locally in the stomach and soon empty, which means the dosage didn't have enough time to sit in the stomach. GRDDS was created to improve the drug's bioavailability and extend its absorption period in order to circumvent this disadvantage.

Oral medication delivery One of the site-specific drug delivery methods is gastroretentive delivery. The targeted site determines how well the medicine is absorbed. The drug forms utilised in gastroretentive drug delivery systems deteriorate at alkaline pH and are either less soluble or slowly soluble with extended bioavailability and absorption⁷.

Factors Affecting Gastro Retentive Time:

1. Density: Floating drug delivery systems have a bulk density less than gastric fluid (~1.004g/mL) and float on top of the stomach's contents. High-density systems use heavy inert materials, causing them to sink to the bottom and be retained in the folds of the stomach.

2. Size and shape: Larger dosage forms, such as those with a diameter greater than 7.5mm, typically have a longer GRT. Certain shapes, like tetrahedrons or rigid rings, have also been shown to improve retention.

3. Single vs. multiple units: Single-unit dosage forms are subject to the "all-or-nothing" emptying of the stomach. Multiple-unit systems, such as small pellets or microparticles, offer more predictable release profiles and a greater safety margin against formulation failure.

4. Adhesive properties: Mucoadhesive or bioadhesive systems use polymers that can bind to the gastric mucosal lining, holding the dosage form in place and prolonging its residence time.

5. Swelling capacity: Expanding or swelling systems are formulated with hydrophilic polymers that absorb gastric fluid and expand to a size larger than the pyloric sphincter, preventing their passage into the small intestine⁸.

6. Polymers and excipients: The choice of polymers (e.g., HPMC, PEO) and other excipients (e.g., gas-generating agents) is critical for achieving the desired floating, swelling, or mucoadhesive properties.

7. Magnetic properties: By incorporating small magnets into the formulation, a magnetic field can be externally applied to the abdomen to guide and retain the dosage form in the stomach⁹.

Physiological Factors:

1. Fed vs. fasted state: In the fasted state, strong peristaltic contractions known as the migrating myoelectric complex (MMC) occur every 1 to 2 hours, which can quickly empty the stomach. In the fed state, these contractions are delayed, leading to a much longer GRT.

2. Nature of the meal: High-caloric meals, especially those rich in fats and proteins, significantly increase GRT. Fatty acids and indigestible polymers can also alter the stomach's motility pattern to mimic the fed state.

3. Viscosity of meal: A high-viscosity meal delays gastric emptying by hindering the movement of stomach contents toward the pylorus.

4. Stomach pH: The pH of the stomach is strongly acidic in a fasted state (pH 1.5–2) but rises significantly after food intake (pH 2–6). This can affect the performance of pH-sensitive gastroretentive systems.

5. Posture: A person's body posture can affect the location of the dosage form within the stomach. An upright position promotes the retention of floating systems, while a supine position can extend the retention time of high-density systems¹⁰.

Patient-Related Factors:

1. Age: Gastric emptying is generally slower in elderly people, especially those over 70, which results in a longer GRT. Infants and young children may have different GRTs.

2. Gender: On average, females have a slower gastric emptying rate than males, which can be influenced by hormonal changes, such as during the menstrual cycle.

3. Disease states and medication: Certain diseases, like diabetic gastroparesis or Crohn's disease, and medications, such as anticholinergics and prokinetic agents, can alter gastric motility and affect GRT¹¹.

Advantages of Grdds:

1. Increased bioavailability: By holding the drug in the stomach and upper part of the small intestine, GRDDS maximize the amount of time it has to be absorbed. This is particularly useful for drugs with a "narrow absorption window," which are primarily absorbed in this specific region.

2. Sustained and controlled drug delivery: GRDDS provide a slow, continuous release of the drug over an extended period. This helps maintain consistent therapeutic drug levels in the bloodstream and avoids peaks and troughs in plasma concentration that can be associated with conventional dosage forms.

3. Improved patient compliance: With a sustained-release effect, GRDDS can significantly reduce the frequency of doses required per day. Fewer doses make it easier for patients to follow their treatment regimen correctly¹².

4. Targeted therapy for local stomach ailments: For drugs that need to act directly on the stomach lining, such as antibiotics for Helicobacter pylori or medication for peptic ulcers, GRDDS ensures prolonged local exposure, enhancing therapeutic effects.

5. Reduced drug waste: By providing a more efficient and prolonged release, GRDDS ensures that a greater proportion of the drug is absorbed before it passes out of the absorption zone. This makes the dosage more economical and reduces waste.

6. Avoidance of drug degradation: For medications that are unstable or poorly soluble at the high pH of the lower gastrointestinal tract, GRDDS protects them by releasing the drug in the acidic environment of the stomach¹³.

7. Overcoming first-pass metabolism: By prolonging gastric retention, GRDDS can be used to manage drugs that undergo significant first-pass metabolism in the liver. A more controlled release can reduce the extent of this effect.

8. Reduced risk of dose dumping: Unlike some other controlled-release systems, GRDDS formulations are designed to prevent the sudden, premature release of the entire drug content. This ensures safer, more predictable delivery.

9. Higher efficiency for short-half-life drugs: Drugs with a short elimination half-life that are cleared quickly from the bloodstream can benefit from a sustained release. GRDDS helps these drugs stay within their effective concentration range for longer.

10. Increased solubility of some drugs: For certain medications that are less soluble in the higher pH of the small intestine, keeping them in the acidic gastric fluid for longer improves their solubility and overall absorption¹⁴.

Disadvantages of GRDDS:

1. These are not suitable candidates for drug which have stability or solubility problem in stomach.

2. Floating system has limitation that it requires high fluid level in stomach for floating and absorption efficiently.

3. The mucoadhesive system has the limitation of high turnover of the mucus layer, thick mucus layer and limitation associated with soluble mucus¹⁵.

4. Gastric retention is affected by many factors such as gastric motility, pH, and food presence. Buoyancy cannot be predicted because these factors are not constant.

5. The swelling formulation can be swelled in the system before reaching the site of the stomach.

6. Longer time required to swell for hydrogel based swelling system¹⁶.

Recent Approaches of GRDDS:

For gastrointestinal disorders, oral control release and sustain release drug delivery systems have advanced significantly in order to prolong drug absorption. This technique maintains an efficient medication concentration and enhances bioavailability in gastroretentive tracks for length of time in the stomach (GIT). When an oral medication (tablet, capsule, or pellet) is taken orally in the stomach, the medication is retained there and released in a regulated way¹⁷.

The medication will be continuously delivered to its absorption site or targeted site because of its controlled and sustained release. It is also a pH-base drug delivery device, meaning that a heavy layer of metal releases the medicine at a specific pH. This stop it from dissolving in the stomach contents and instead disintegrate it at the intended location. The current study discusses several gastro-retentive drug delivery system approaches that have emerged as the most popular methodology in the field of controlled release and site-specific drug administration in recent years.

Approaches for Gastroretentive Drug Delivery Systems (GRDDS) include floating, mucoadhesive, high-density, and swelling/expanding systems, each designed to prolong the time a drug stays in the stomach. Floating systems stay buoyant, mucoadhesive systems stick to the stomach lining, high-density systems sink to the bottom, and swelling/expanding systems get too large to pass through the pyloric sphincter. Magnetic systems, which use external magnets to retain the formulation, are also a method¹⁸.

Figure 4: Approaches of GRDDS.

1. Floating Drug Delivery System:

In 1968, Sir Davis first presented the floating medicine delivery technique. Since the bulk density of the floating medication delivery device is less than that of stomach juice, it stays. It releases the medicine in a controlled manner over an extended period of time in the stomach or targeted region. Over an extended period of time, the rate of stomach emptying is unaffected by floating medication administration.

Drug release in the stomach occurs after the gastric emptying of the residual system. Enhance the drug's bioavailability, regulate its plasma levels, and lengthen its stomach retention period¹⁹.

Figure 5: Floating Drug Delivery System.

2. Effervescent System-

Swellable polymers like tartaric acid, HPMC, chitosan, and effervescent compounds like citric acid and sodium bicarbonate are used to form the effervescent system matrix. The GIT's stomach pH and absorption may be improved by effervescent preparation. Effervescent tablets have a higher bioavailability than regular tablets. When an effervescent dosage form (tablet) containing citric acid, tartaric acid, or sodium bicarbonate reacts in the stomach, carbon dioxide is produced. Citric acid is added to sodium bicarbonate in a 0:76:1 ratio to produce effervescent carbon dioxide. medication reservoirs in effervescent systems allow for controlled or sustained medication release²⁰.

Figure 6: Effervescent System

3. Non-effervesent system:

When a non-effervescent medication (dosage form tablet, capsule, pellets) is taken orally, it comes into touch with the gastric fluid in the stomach, which has a pH range of 1 to 3. It swells and becomes bulky, losing its density of less than 1.The non-effervescent dosage form's gel-like shape serves as a reservoir and permits controlled content release for an extended period of time. The finest non-effervescent methods are porous on the surface, which creates an osmatic situation and causes the dosage form to swell significantly or several times more than other oral dosage forms when it reacts with gastric fluid. The dosage form is pushed to the pylorus by the stomach's gastric concentration as a result, but the swelling increases²¹.

4. Raft forming system:

GERD, or stomach esophageal reflux disease, is the primary condition for which the raft forming technology is utilised. When the raft producing mechanism comes into contact with gastric fluid, a viscous cohesive gel is formed. The carbonate and bicarbonate in the raft-forming system cause the dosage form to become bulky and are in charge of releasing carbon dioxide to reduce the density of the system. The gel-forming substance in the raft-forming mechanism is sodium alginate, which reacts with stomach fluid to form raft and stop stomach contents from refluxing into the oesophagus²².

Future Perspectives of Gastro-retentive Drug Delivery Systems (GRDDS):

As potent platforms for enhancing the bioavailability, therapeutic effectiveness, and dosing ease of medications that gain from extended stomach residency, gastroretentive drug delivery systems are still developing. Numerous possible future directions are indicated by research and technological trends:

1. Advanced Smart Polymers and Materials:

Future GRDDS will depend more and more on stimuli-responsive (smart) polymers that can respond to:

· pH variation

· Enzymes and Temperature

· Stress caused by Mechanics

By enabling triggered buoyancy, tunable swelling, or on-demand drug release, these materials can increase accuracy and decrease the frequency of dosage²³.

2. Combining Nanotechnology:

The use of nanotechnology will increase due to:

· Floating systems embedded with nanoparticles

· Mucoadhesive nanoparticles

· matrices that are nanofibrous²⁴.

3. Additive manufacturing, or 3D printing:

3D printing has the potential to revolutionize GRDDS by enabling:

· Customized dose forms for each patient

· Tablets having several layers that have regulated swelling, floating, or mucoadhesive characteristics

· Intricate shapes that maximize stomach retention

· Precision medicine in oral medication distribution is made possible by this.

Particularly for poorly soluble medications, they can increase surface area, drug-loading capacity, and bioavailability²⁵.

4. Multifunctional Hybrid Systems:

Two or more gastroretentive processes will be combined in future systems, such as:

· Mucoadhesive + floating

· Expandable and swelling

· Magnetic navigation combined with floating Retention time, drug release control, and resilience in fluctuating GI²⁶.

5. Designs Inspired by Biology:

Inspired by nature, particularly by some species' bioadhesive processes, scientists are investigating:

· Bioinspired mucoadhesives, such as chemistry based on catechol that is inspired by mussel adhesion

· Expandable structures based on the swelling of plant seeds Through controlled deterioration, they might increase retention and guarantee safety.

6. Enhanced AI-Based Design and In-Silico Modeling:

Computational modeling and AI will assist:

· Estimate buoyancy and mechanical stability

· Model the kinetics of drug release and stomach motility

· Reduce the number of trial-and-error experiments to optimize formulation.

The GI tract's digital twins may make development cycles more effective²⁷.

7. Improved Biocompatibility and Safety:

Concerns of gastrointestinal blockage will be addressed in future studies.

· Material buildup

· Biocompatibility with time

The creation of materials that are completely digestive, biodegradable, or ecologically neutral will be a major priority²⁸.

8. GRDDS for Biologicals, Proteins, and Peptides:

Developments in permeation enhancers and protective materials might enable GRDDS to distribute not just tiny compounds but also:

· Peptides

· Tiny proteins

· Agents that alter the microbiome

This might make gastroretentive systems more therapeutically useful than traditional medications²⁹.

9. Retentive Systems with External Control and Magnetic Guidance:

Among the innovations are:

· GRDDS with magnetic control Systems that are triggered by electromagnetic fields or external ultrasound

These are particularly helpful for localized gastric disorders because they provide focused release and adjustable gastric retention³⁰.

10. Commercialization and Industrial Translation:

Future developments in the sector include:

· Enhanced manufacturing scalability

· Regulations pertaining to 3D-printed systems and smart materials

· Production of customized GRDDS at a reasonable cost

This will enable broader medication uptake³¹.

CONCLUSION:

Gastroretentive drug delivery systems continue to gain significant attention as a promising platform for enhancing the therapeutic performance of oral medications. With the growing demand for improved bioavailability, reduced dosing frequency, and targeted delivery to the upper gastrointestinal tract, GRDDS offer several advantages over conventional delivery methods. Future advancements are expected to focus on the development of smart polymers, nanotechnology-enabled systems, and 3D-printed personalized dosage forms that provide precise control over gastric retention and drug release. Additionally, the emergence of hybrid multifunctional systems, bioinspired materials, and AI-assisted formulation design will further expand the capabilities and safety of these technologies. As research integrates innovative materials, computational tools, and patient-specific approaches, GRDDS are poised to become a highly reliable and versatile platform for the next generation of oral drug delivery. The future of GRDDS is moving toward smart, personalized, hybrid, and nanotechnology-enabled systems that provide superior control over drug release and gastric retention. With advances in material science, 3D printing, and digital modeling, GRDDS will play an increasingly central role in improving oral drug delivery for both existing and novel therapeutics. The future of gastroretentive drug delivery systems is highly promising, driven by rapid advancements in materials science, nanotechnology, and personalized medicine. Emerging innovations such as smart stimuli-responsive polymers, hybrid multifunctional systems, and 3D-printed dosage forms are expected to greatly enhance the precision, reliability, and adaptability of GRDDS. These technologies will enable better control over gastric retention and drug release, improving therapeutic outcomes and patient compliance. Furthermore, the integration of bioinspired materials and AI-assisted formulation tools will support the development of safer, more efficient, and patient-specific gastroretentive platforms. Overall, GRDDS are poised to evolve into highly sophisticated systems that expand their applicability to a broader range of drugs and play an increasingly significant role in the future of oral drug delivery.

SUMMARY:

Gastroretentive drug delivery systems (GRDDS) aim to prolong the residence of dosage forms in the stomach, improving the absorption and therapeutic effectiveness of drugs that benefit from gastric retention. Future developments in GRDDS focus on using smart, stimuli-responsive polymers, nanotechnology, and 3D-printing to create more precise, adaptable, and patient-specific dosage forms. Hybrid systems combining floating, mucoadhesive, swelling, and expandable mechanisms are expected to enhance reliability in the variable gastric environment. Advances in computational modeling, artificial intelligence, and bioinspired materials will support the design of safer and more efficient formulations. Overall, GRDDS are moving toward highly controlled, personalized, and multifunctional platforms, offering improved bioavailability, reduced dosing frequency, and expanded applicability to new classes of drugs. Gastroretentive drug delivery systems (GRDDS) are designed to remain in the stomach for an extended period, improving the absorption and effectiveness of drugs that act in the upper gastrointestinal tract. Future advancements in GRDDS will focus on smart polymers, nanotechnology, 3D printing, and hybrid systems that combine multiple retention mechanisms. These innovations will make formulations more precise, personalized, and reliable. With improvements in safety, materials, and computational design tools, GRDDS are expected to become a more advanced and widely used approach for enhancing oral drug delivery. The future of Gastroretentive Drug Delivery Systems (GRDDS) is centered on developing more intelligent, efficient, and patient-tailored technologies. Advancements in smart polymers, nanotechnology, and 3D printing will enable precise control over gastric retention and drug release. Hybrid systems combining floating, swelling, mucoadhesive, and expandable mechanisms are expected to enhance reliability in the dynamic gastric environment. Bioinspired materials and biodegradable designs will improve safety and compatibility. Additionally, computational modeling and artificial intelligence will accelerate formulation design and optimization. Overall, future GRDDS will be more innovative, personalized, and multifunctional, offering improved therapeutic outcomes and expanding their application to a wider range of drugs.

REFERENCES:

1. Nitave SA, Patil VA, Kagalkar AA. Review on gastro retentive drug delivery system (GRDDS). Int. J. Pharm. Sci. Rev. Res. 2014; 27:90-5.

2. Vishwakarma SK, Mishra JN, Vishwakarma DK. A Review on GRDDS Recent Advances in Drug Delivery Systems and Its Application. World Journal of Pharmaceutical Research. 2021 Jul 14; 10(11): 1159-75.

3. Singh M, Das MK. A Comprehensive Review on Role of Natural Polymers in Gastro Retentive Drug Delivery System (GRDDS). Drug Delivery Letters. 2024 Oct 14.

4. Tripathi J, Thapa P, Maharjan R, Jeong SH. Current state and future perspectives on gastroretentive drug delivery systems. Pharmaceutics. 2019 Apr 20;11(4):193.

5. Kumar V, Somkuwar S, Singhai AK, Kumar V, Somkuwar S, Singhai AK. A recent update on gastro retentive drug delivery systems. GSC Biol. Pharm. Sci. 2024; 27:125-44.

6. Dubey A, Ovais M, Bisen AC, Rajendiran A. Advancements and Challenges in Gastroretentive Drug Delivery Systems: A Comprehensive Review of Research Innovation, Technologies, and Clinical Applications. Recent Advances in Drug Delivery and Formulation. 2025 Apr 28.

7. Ramavath VN. A review on gastro retentive drug delivery system. International Journal of Indigenous Herbs and Drugs. 2025 Aug 9:13-7.

8. Zanke AA, Gangurde HH, Ghonge AB, Chavan PS. Recent advance in gastroretantive drug delivery system (GRDDS). Asian Journal of Pharmaceutical Research. 2022;12(2):143-9.

9. Sharma G, Nautiyal U, Ahmad S. An overview on gastroretentive drug delivery system (GRDDS). International Journal of Health and Biological Sciences. 2019;2(2):1-8.

11. Pawar M, Patkal R, Bhalekar P, Karad O. A Review on Gastro Retentive Drug Delivery System (GRDDS). International Journal of Scientific Research and Technology. 2025 Feb 5.

12. Rathod HJ, Mehta DP, Yadav JS. A review on gastroretentive drug delivery systems. PharmaTutor. 2016 Jul 1;4(7):29-40.

13. Niranjanbhai BD, Mahendrakumar VN, Surendran CS, Viral S, Upadhyay UM. Advances in grdds: raft forming system a review. Journal of Drug Delivery and Therapeutics. 2012;2(5):123-8.

14. Bhandwalkar MJ, Dubal PS, Tupe AK, Mandrupkar SN. Review on gastroretentive drug delivery system. Asian J. Pharm. Clin. Res. 2020 Dec 7;13(12):38-45.

15. Pachpor MS. A Systemic Review on: Formulation and Evaluation of Gastroretentive Tablet. World Journal of Pharmaceutical Sciences. 2025 Jun 14.

16. Mandal UK, Chatterjee B, Senjoti FG. Gastro-retentive drug delivery systems and their in vivo success: A recent update. Asian journal of pharmaceutical sciences. 2016 Oct 1;11(5):575-84.

17. Badoni A, Ojha A, Gnanarajan G, Kothiyal P. Review on gastro retentive drug delivery system. The pharma innovation. 2012 Oct 1;1(8, Part A):32.

18. Waqar MA, Mubarak N, Khan AM, Khan R, Shaheen F, Shabbir A. Advanced polymers and recent advancements on gastroretentive drug delivery system; a comprehensive review. Journal of drug targeting. 2024 Jul 2;32(6):655-71.

19. Laxmi KD, Sree GS, Kapileshwer H, Devi J, Sandhyaja J. A Review On Gastro Retentive Drug Delivery System (Grdds).

20. Zaid M, Kalam I, Majaz Q. Gastro Retentive Drug Delivery System. International Journal of Research in Pharmacy and Allied Science. 2024 Nov 8;3(5):6-16.

21. Kumar A, Kumari S, Srivastava T. A review on Gastro retentive floating drug delivery system (GRDDS). Organized by. 2018;418.

22. Rouge, N., Buri, P., and Doelker, E. (1996). Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. International Journal of Pharmaceutics, 136(1–2), 117–139.

23. Singh, B. N., and Kim, K. H. (2000). Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. Journal of Controlled Release, 63(3), 235–259.

24. Streubel, A., Siepmann, J., and Bodmeier, R. (2006). Gastroretentive drug delivery systems. Expert Opinion on Drug Delivery, 3(2), 217–233.

25. Arora, S., Ali, J., Ahuja, A., Khar, R. K., and Baboota, S. (2005). Floating drug delivery systems: A review. AAPS PharmSciTech, 6(3), E372–E390.

26. Kagan, L., Lapidot, N., Afargan, M., and Hoffman, A. (2010). Gastroretentive dosage forms: New technologies for enhanced absorption. Current Pharmaceutical Design, 16(10), 1191–1201.

27. Pawar, V. K., Kansal, S., Garg, G., Awasthi, R., Singodia, D., and Kulkarni, G. T. (2011). Gastroretentive dosage forms: A review with special emphasis on floating drug Delivery Systems. Drug Delivery, 18(2), 97–110.

28. Park, K. (2014). Controlled drug delivery systems: Past forward and future back. Journal of Controlled Release, 190, 3–8.

29. Hoffman, A. S. (2012). Hydrogels for biomedical applications. Advanced Drug Delivery Reviews, 64, 18–23.

30. Preis, M., Woertz, C., Schneider, K., Kukawka, F., Broscheit, J., and Breitkreutz, J. (2015). 3D printing in pharmaceutical sciences: A review of the state of the art and future perspectives. Advanced Drug Delivery Reviews, 108, 39–50.

31. Kotreka, U. K., and Adeyeye, M. C. (2011). Gastroretentive floating drug delivery systems: A review. Journal of Pharmacy Research, 4(11), 4181–4188.

32. Jassal M, Nautiyal U, Kundlas J, Singh D. A review: Gastroretentive drug delivery system (grdds). Indian Journal of Pharmaceutical and Biological Research. 2015 Jan 1;3(1):82.

Received on 05.01.2026 Revised on 02.04.2026

Accepted on 28.05.2026 Published on 06.07.2026

Available online from July 20, 2026

Asian J. Pharm. Res. 2026; 16(3):355-362.

DOI: 10.52711/2231-5691.2026.00052

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.